Surrozen, Inc.

Healthcare · Biotechnology · United States

Last price 29.46 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 515.41M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular ag...